Table 1.
Baseline characteristics.
| Pt | Age/Sex | Antibodies | ILD Severity | Key Treatments | Lung Tx | Latest FVC | DLCO | Current Status |
|---|---|---|---|---|---|---|---|---|
| 1 | 22/F | MDA5+ | ARDS | RTX, Tac, IVIG, Endoxan, PEX | No | 59 % | 72 % | Stable |
| 2 | 51/M | MDA5+ | ARDS | RTX, MMF, IVIG, Tac | Yes | FEV1 3.7L | 53 % | Stable post-transplant |
| 3 | 69/M | MDA5+ | RP-ILD | TOCI, MMF, RTX, IVIG | No | 54 % (stable) | 53 % (stable) | Controlled disease |
| 4 | 54/F | MDA5+ | Mild ILD | MMF, RTX, IVIG | No | 94 % | 76 % | Good control |
| 5 | 53/F | MDA5+ | Moderate ILD | RTX, Tac, Steroids | No | 102 % | 85 % | Stable, fibromyalgia symptoms |
Abbreviations: ARDS: acute respiratory distress syndrome; DLCO: diffusion capacity for carbon monoxide; Endoxan: cyclophosphamide; F: female; FEV1: forced expiratory volume in 1 second; FVC: forced vital capacity; ILD: interstitial lung disease; IVIG: intravenous immunoglobulins; M: male; MDA5: melanoma differentiation-associated gene 5; MMF: mycophenolate mofetil; PEX: plasmapheresis; Pt: patient; Ro52: anti-Ro52 antibody; RP-ILD: rapidly progressive interstitial lung disease; RTX: rituximab; Tac: tacrolimus; TOCI: tocilizumab; Tx: transplantation.